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Amyloid β (Aβ) accumulation and its aggregation is characteristic molecular feature of
the development of Alzheimer’s disease (AD). More recently, Aβ has been suggested
to be associated with retinal pathology associated with AD, glaucoma and drusen
deposits in age related macular degeneration (AMD). In this study, we investigated the
proteins and biochemical networks that are affected by Aβ in the 661 W photoreceptor
cells in culture. Time and dose dependent effects of Aβ on the photoreceptor
cells were determined utilizing tandem mass tag (TMT) labeling-based quantitative
mass-spectrometric approach. Bioinformatic analysis of the data revealed concentration
and time dependent effects of the Aβ peptide stimulation on various key biochemical
pathways that might be involved in mediating the toxicity effects of the peptide. We
identified increased Tau phosphorylation, GSK3β dysregulation and reduced cell viability
in cells treated with Aβ in a dose and time dependent manner. This study has delineated
for the first-time molecular networks in photoreceptor cells that are impacted early
upon Aβ treatment and contrasted the findings with a longer-term treatment effect.
Proteins associated with ribosomal machinery homeostasis, mitochondrial function and
cytoskeletal organization were affected in the initial stages of Aβ exposure, which may
provide key insights into AD effects on the photoreceptors and specific molecular
changes induced by Aβ peptide.
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INTRODUCTION
Amyloid beta (Aβ) is a highly toxic and hallmark aggregate-prone peptide associated with
Alzheimer’s disease (AD) pathology. The disease affects around 5.7 million people in USA
alone and is predicated to rise and affect over 13.8 million people by the middle of the century
in USA (2018; Alzheimer’s Association, 2018). Recent studies indicate that the retina which
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is a neural offshoot of the brain, undergoes pathological
changes during AD pathogenesis (Gupta et al., 2016a,b; Golzan
et al., 2017). Increasing lines of evidence have shown that
specific AD like pathology (development of amyloid plaques
and neurofibrillary tangles) in the brain can also be found in
the retina (Koronyo-Hamaoui et al., 2011a). Particularly, Aβ
accumulation has been reported in the retinas of human AD
subjects (Goldstein et al., 2003; Koronyo-Hamaoui et al., 2011b;
Koronyo et al., 2017). The deposition of Aβ, derived from
abnormal processing of amyloid precursor protein (APP) has
also been found in the retinas of AD transgenic mice (Kin
Chiu, 2013; Gupta et al., 2016b). Furthermore, Aβ accumulation
and increased APP reactivity has been identified in other
neurodegenerative disorders of the retina such as in glaucoma as
well as in the drusen deposits in age relatedmacular degeneration
(AMD; Anderson et al., 2004; Gupta et al., 2014; Zhao et al.,
2015). These findings highlight the common features shared by
AD, AMD, and glaucoma in the context of Aβ amyloidosis. AMD
is associated with the loss of photoreceptor neurons and anti-Aβ
therapy has been shown to be protective and prevent vision loss
(Ding et al., 2011). Aβ neutralization in the retina using specific
antibodies was also shown to impart protection in AD animal
models and in experimental glaucoma implicating its negative
impact on the retinal neurons (Guo et al., 2007; Ding et al., 2008;
Liu et al., 2009). In contrast, Aβ administration either through
the subretinal injections or intravitreal space exhibits neural toxic
properties (Guo et al., 2007; Liu et al., 2015).
The abnormal processing of Aβ and its oligomerization
leads to formation of Aβ assemblies and activation of apoptotic
pathways that are detrimental to the cell functioning and
induce synaptic degeneration (Benilova et al., 2012). Other
studies associate the toxicity of the Aβ peptides linked to
inflammation and retinal degeneration (Ning et al., 2008; Liu
et al., 2013). Retinal abnormalities such as sensory deficiencies,
visual impairment and functional deficits have been reported in
early AD (Berisha et al., 2007; Cheung et al., 2015; Golzan et al.,
2017; Gangoda et al., 2018).
Despite emerging evidence on involvement of Aβ in
retinal abnormalities, the precise mechanisms involved in Aβ
accumulation and its subsequent effects on the retinal cells have
remained ill-defined. To delineate the global level proteome
expression changes induced by Aβ on the photoreceptor cell
in culture, we, used tandem mass tag (TMT) quantitative
proteomics, to assess the time and dose dependent cytotoxic
effects of Aβ 1–42 peptide. Cultured neuronal cells have the
capacity to internalize Aβ 1–42 from the culture media and
exhibit toxicity effects such as ROS production within lysosomes
and impairment of lysosomal membrane proton gradient leading
to cell death (Ditaranto et al., 2001). Of note, an increasing
body of evidence highlights that toxic effects of Aβ are mediated
through oxidative stress, impairment of cytoskeletal organization
and mitochondrial dysfunction which are implicated in AD,
but have also been reported in AMD and glaucoma (Ratnayaka
et al., 2015; Gupta et al., 2016a; Masuzzo et al., 2016). Our
results establish the toxic effects of Aβ on photoreceptor cells and
suggest that Aβ may specifically perturb biochemical pathways
associated with protein synthesis, RNA processing, oxidative
phosphorylation and cytoskeleton organization in a time and
concentration dependent manner.
MATERIALS AND METHODS
Cell Culture and Treatments
Mouse retinal cells (661 W cells) were grown in DMEM
medium containing 10% (v/v) fetal bovine serum (FBS), 1%
(v/v) penicillin/streptomycin (Thermofisher), in presence of 5%
CO2 at 37◦C incubator for 24 h, and then transferred into new
plates to culture for another 24 h in the incubator (Gupta et al.,
2015). Aβ 1–42 fragment (Sigma) was freshly prepared each
time by dissolving in PBS and added into the culture plates
to a final concentration of 5µm or 25µm for either 6 h or
24 h at 37◦C as reported previously (Hansson Petersen et al.,
2008). pTau Ser202/Thr205 (Mn1020, 1:1,000; Thermo Fisher),
Tau (Tau46 40,191:1,000), pGSK3β Ser9 (93,361:1,000), GSK3β
(93,151:1,000; Cell Signaling Technology), Anti-beta Actin
[(AC-15) ab6276, 1:10,000] (Abcam). Horseradish peroxidase
conjugated anti-rabbit and anti-mouse secondary antibodies
(R&D Systems) were used to visualize the bands. Cells were
separately harvested after treatments with Aβ for 6 and 24 h.
Therefore, there were four separate sets of samples from
four separate treatments consisting of two concentrations and
two time-points: treatment 1 (T1_5 µm_6 h), treatment 2
(T2_5 µm_24 h), treatment 3 (T3_25 µm_6 h), and treatment 4
(T4_25 µm_24 h). Four biological replicates were prepared for
each specific treatment, along with five control replicates. Cells
were stored at −80◦C until protein extraction.
Protein Sample Preparation and Western
Blotting
Cells were lysed in 200 µL ice-cold lysis buffer (50 mM
Tris-HCl, pH7.5, 150 mM NaCl, 1%NP40, 1 mM EDTA,
0.1% SDS) containing protease inhibitor and sonicated using
a probe sonicator (40 HZ × 2 pulses × 15 s) with 30 s
interval on ice. Supernatant was transferred to a new tube and
insoluble debris was removed by centrifugation at 13,000 rpm
for 15 min at 4◦C. Extracted proteins were reduced with 20 mM
dithiothreitol (DTT) for 15 min at room temperature, and
then alkylated with 50 mM iodoacetamide for 30 min in the
dark at room temperature. The alkylation reaction was then
quenched with additional 40 mM DTT for 15 min in the dark.
Methanol/chloroform was applied to precipitate proteins and
remove interfering detergents and other contaminants (Wessel
and Flugge, 1984). The protein pellet was left to dry and
then resuspended with 200 µL of 8 M urea in 100 mM
Tris-HCl (pH = 8.5). Protein concentration was measured with
bicinchoninic acid (BCA) assay kit (Pierce, Rockford, LI, USA)
with bovine serum albumin as standards. The proteins (200 µg)
were digested using trypsin (Promega, Madison, WI, USA) with
a 50:1 protein: enzyme ratio and incubated at 37◦C overnight.
Digested peptides were then acidified with trifluoroacetic acid
(TFA) to a final concentration of 1% (pH 2–3) and desalted
using SDB-RPS (3 M-Empore) Stage-tips. Samples were eluted
from Stage-tip using 200 µL of 80% acetonitrile/5% ammonium
hydroxide. Dried peptides were dissolved in 100 mM HEPES
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 February 2019 | Volume 12 | Article 24
Deng et al. Effect of Amyloid β on the Retinal Photoreceptor Cells
(pH = 8.0) and peptide concentration was measured using
Micro BCA assay kit (Pierce, Rockford, LI, USA). For western
blotting, 30 µg of protein was separated using 10% SDS-PAGE
and transferred to PVDF membrane for blotting. 5% skimmed
milk buffer in Tris-HCL buffer containing saline was used to
block the western blotting membrane. The primary antibody
was added to the blot and incubated for the night at 4◦C.
This was followed by thoroughly washing the blots with Tris
buffer saline (three times) and subsequently incubating the blots
with horseradish peroxidase conjugated secondary antibody. The
blots were extensively washed again, and images taken using the
western blotting densitometric imager. The blots were developed
using chemiluminescent substrate within the linear range of
detection and data quantified and plotted using Graph pad prism
as described previously (Gupta et al., 2010, 2012, 2017).
TMT Labeling
One-hundred microgarm of peptides from each sample were
used for TMT labeling (Thermofisher) with 0.8 mg of labeling
reagents per reaction. Labeling was carried out at room
temperature for 1 h with occasional vortexing. To quench
any remaining unbound TMT reagents, 8 µL of 5% fresh
hydroxylamine was added, followed by vortexing and incubation
at room temperature for 15 min. To accommodate 21 samples
(five control replicates and 16 samples from four treatments), two
separate 10-plex TMT experiments were carried out (Figure 1).
For each TMT experiment, respective 10 labeled samples were
combined and dried in a vacuum centrifuge. Peptides were
reconstituted in 1% formic acid and desalted using Sep-Pak
C18 cartridges (Waters, Milford, MA, USA). After high pH
reversed-phase peptide fractionation, peptides were consolidated
into 16 fractions. Dried fractions were resuspended in 1% formic
acid, and then desalted again using SDB-RPS (3M-Empore) stage
tips (Chitranshi et al., 2018).
LC-MS/MS Analysis
Fractionated and dried peptides were reconstituted in 40 µL of
0.1% formic acid and analyzed on a Q Exactive Orbitrap mass
spectrometer (Thermo Scientific, San Jose, CA, USA) coupled to
an EASY-nLC1000 nanoflow HPLC system (Thermo Scientific,
San Jose, CA, USA). Reversed-phase chromatographic separation
was performed on an in-house packed reverse–phase column (75
µm × 10 cm with Halor 2.7 µm 160 Å ES-C18 (Advanced
Materials Technology). Labeled peptides were separated for 2 h
using a gradient of 1%–30% solvent B (99.9% acetonitrile/0.1%
formic acid) and Solvent A (97.9% water/2% acetonitrile/0.1%
formic acid). The Q Exactive mass spectrometer was operated
in the data-dependent acquisition (DDA) mode to automatically
switch between full MS and MS/MS acquisition. Following the
Full MS scan spectra (from m/z 350–1,850), were acquired at
resolution of 70,000 at m/z 400 and an automatic gain control)
target value of 1 × 106 ions. The top 10 most abundant ions were
selected with precursor isolation width of 0.7 m/z for higher-
energy collisional dissociation (HCD) fragmentation. HCD
normalized collision energy was set to 35% and fragmentation
ions were detected in the Orbitrap at a resolution of 70,000.
Target ions that had been selected for MS/MS were dynamically
excluded for 90 s.
Database Searching
Raw data files were processed in Proteome Discoverer V2.1
(Thermo Scientific, San Jose, CA, USA) using search engines
Mascot (Matrix Science, WI, UK). Data were matched against
the reviewed SwissProt Mus musculus protein database
(16,953 sequences, Feb 2018). The MS1 tolerance was
set to ± 10 ppm and the MS/MS tolerance to 0.02 Da.
Carbamidomethyl (C) was set as static modification, while
TMT 10-plex (N-term, K), Oxidation (M), Deamidation
(N, Q), Glu->pyro-Glu (N-term E), Gln->pyro-Glu (N-
term Q) and Acetylation (Protein N-Terminus) were set
as dynamic modifications. Percolator algorithm was used
to discriminate correct from incorrect peptide-spectrum
matches, and calculate statistics including q-value (FDR)
and posterior error probabilities. Search results were further
filtered to retain protein, peptide and PSM with FDR of <1%
and only master proteins assigned via protein grouping
algorithm were retained. Relative quantitation of proteins
was achieved by pairwise comparison of TMT reporter ion
signal to noise (S/N) ratios (in case of availability across
all channel if not intensities are used), for example, the
ratio S/N of the labels for each of treatment replicates
(numerator) vs. the labels of their corresponding control
replicates (denominator).
Analysis of Differentially Expressed
Proteins
Proteins were further analyzed using the in house developed
TMTPrepPro analysis pipeline (Mirzaei et al., 2017b). The
TMTPrepPro scripts are implemented in the R programming
language and are available as an R package, which is accessed
in our group through a graphical user interface provided via
a local GenePattern server. All protein ratios with respect to
the pooled control reference (label-126) were extracted and
combined across runs. Two separate approaches were considered
for the data analysis: the analysis of variance (ANOVA)
analysis of all four treatments, and the pairwise comparisons of
each treatment to the control. Differentially expressed proteins
based on ANOVA comparison of log-transformed ratios were
identified and clustered to check the conditions of Aβ peptide
treatment and controls were well separated. For the pairwise
comparisons, relative quantitation of protein abundance in Aβ
peptide treatments compared to control was derived from the
ratio of the TMT label S/N detected in each treatment to control,
and differentially expressed proteins were identified based on
student t-tests between control and treatment ratios. The overall
fold changes were calculated as geometric means of the respective
ratios. Differential expression required proteins to meet both
a ratio fold change [>1.20 (up-regulated) or <0.833 (down-
regulated)] and a p-value cut-off (t-test p-value< 0.05; Margolin
et al., 2009; Kammers et al., 2015). The identified differentially
expressed proteins through the pairwise comparisons were
subjected to pathways enrichment analysis using Ingenuity
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FIGURE 1 | Tandem mass tag (TMT) labeling strategies and experimental workflow.
Pathway Analysis (IPA)1; core analyses for each comparison
were followed up with a comparison analysis. Identified proteins
were mapped to genes using Ingenuity Pathway Knowledge
Base (IPKB). Significant interaction networks (p < 0.05) and
molecular and cellular functions were identified based on known
protein–protein interactions in the Ingenuity knowledgebase.
Networks naming is based on the most common functional
group(s) present. Canonical pathway analysis is used to identify
the function-specific genes amongst the up and down-regulated
proteins. In addition, as a separate orthogonal approach, the
differentially expressed proteins identified with ANOVA analysis
were further classified according to pathways and biological
processes using the Cytoscape stringApp plugin installed2.
Significantly changed proteins were loaded into Cystoscope, and
theMusMusculus database in the StringDBwas selected to reveal
the protein interactions in the context of enriched pathways.
MTT Assay for Cell Viability
661 W cells were grown in culture plates until around 85%
confluency was achieved. The cells were then subjected to MTT
(Sigma) treatment (0.5 mg/mL) in plates treated with different
concentration of Aβ at indicated time-points and incubated at
37◦C for 3 h as previously described (Chitranshi et al., 2017). The
cells were lysed gently shaken and absorbance taken at 570 nm
followed by plotting the results.
RESULTS
Differential Effects of Aβ on the Proteome
Profile of Photoreceptors Cell Line
We identified 5,837 proteins from 661 W photoreceptor cells
[treated with various concentrations (5 and 25 µM) of Aβ at
1http://www.ingenuity.com/index.html
2http://apps.cytoscape.org/apps/stringapp
both 6 and 24 h], which were quantified by multiple peptides
at an initial protein FDR of less than 1% (Supplementary
Table S1). There were 380 proteins identified as differentially
expressed between all treatments via an ANOVA (p-value<0.05,
maximum absolute value of fold change ≥1.2). Hierarchical
clustering analysis of proteins with differential abundance
(380 proteins based on ANOVA analysis) illustrated the overall
consistency of up or down regulation within 6 h treatments
and 24 h treatments (Figure 2 and Supplementary Table S2).
The proteome profile was relatively similarly affected when cells
were treated for 6 h with either 5 or 25 µM Aβ concentrations.
A similar distribution pattern of the differentially expressed
proteins was also observed amongst the cells that were treated for
24 h with either 5 or 25 µM Aβ concentrations. This suggested
that duration of treatment with Aβ was a key factor in regulating
proteome changes in the 661 W photoreceptor cells.
For the four pairwise comparisons, quantified proteins
observed to be significantly regulated in treatments t-test, p-value
≤0.05 and relative change from control at least ±20% (≥1.2 or
≤0.83-fold change) are shown in Figure 3A and Supplementary
Table S3. A comparison between the control and experimental
groups indicated 61 and 37 proteins, respectively downregulated
upon treatment with 5 and 25 µM concentrations of Aβ at 6 h.
In contrast, 43 and 31 proteins were respectively upregulated
at these two concentrations at this time point. For the 24 h
treatment group, we observed 8 and 33 proteins respectively
downregulated while 33 and 71 proteins were up-regulated at
5 µM and 25 µM treatment groups. The highest number of
down-regulated proteins was identified in the 5 µM treatment
group at 6 h and the greatest number of up-regulated proteins
was identified in the cells treated with 25 µM concentration
for 24 h. Venn diagram plots further indicated that almost
equal number of proteins was differentially expressed between
the 6 and 24 h time-points (combined changes at 5 and
25 µM). However, when the data was plotted separately with
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respect to different Aβ treatment concentrations keeping the
time constant, a higher number of differentially expressed
proteins were identified at 5 µM (6 h) and 25 µM (24 h)
concentrations compared to the other two groups. Interestingly,
the number of differentially expressed proteins across various
Venn plots remained largely similar (Figures 3B–D). The
top 10 differentially regulated proteins (3.5 to −1.3-fold
change) in the two Aβ treatment groups (5 and 25 µM)
at 6 and 24 h time-points are listed (Figure 4A). Nucleolar
pre-ribosomal-associated protein 1 (URB1) and U6 snRNA-
associated LSM1 proteins were consistently upregulated at both
5 and 25 µM treatment groups at 24 h. RNA binding motif
containing proteins such as RBMX and RBM47 were also
up-regulated. Interestingly, ribosomal proteins such as Rpl29,
RPS19, Rpl36a were downregulated in the photoreceptor cells
treated with Aβ for 6 h. In contrast, histone methyltransferase
complex regulatory subunit DPY30 expression was suppressed
specifically in the groups treated with Aβ for 24 h.
Pathway Classification of the Differentially
Expressed Proteins
Biochemical pathway analysis was used to reveal the molecular
mechanisms, as well as the disease and biological processes
affected in cells treated with Aβ. To achieve this, IPA was
performed on the differentially expressed proteins identified
in each comparison tests. The canonical pathway analysis
(Figure 4B) in four treatments revealed that transcription
signaling pathways particularly mediated through Elf2, elf4 and
p70S6K were differentially affected. Oxidative phosphorylation
and mitochondrial dysfunction linked pathways were also
affected at both the Aβ concentrations with respect to time
(6 and 24 h). Protein kinase A and Sirtuin linked signaling
were similarly affected with maximum effect on differentially
expressed proteins observed at 6 h time-point. Autophagy
was an interesting pathway that was primarily induced at
25 µM concentration suggesting the potential toxicity effects.
The network of interacting proteins found to be differentially
expressed among all groups based on ANOVA (Figure 4C)
was generated using the Cytoscape network environment with
the StringDB plugin. Several enriched KEGG pathways are
indicated on the network diagram, which complemented and
reinforced the results of the analysis using IPA based on pairwise
comparison. Apart from similar pathways identified in IPA
(ribosome, sirtuin signaling and oxidative phosphorylation),
other pathways such as spliceosome, lysosome, actin cytoskeleton
and keratin filaments were uniquely enriched in STRING
analysis. Differentially expressed proteins in these pathways were
highlighted visually and shown in (Figure 5). The expression
regulation shown in Figure 5 reinforced the results of the IPA
analysis based on pairwise comparison. For instance, regulation
of proteins in the ribosome dysfunction pathway was prominent
in 5 µm_6 h (Figures 4B, 5) and proteins in sirtuin signaling
pathway were significantly regulated in all treatment groups
(Figures 4B, 5). All these results revealed the consistency
within two different approaches based on pairwise comparison
and ANOVA analysis. Effects on these proteins and pathways
reflected that Aβ exhibits a differential effect with respect to both
the concentration and time, but the highest disparity is observed
with respect to timing rather than the indicated concentrations
(5 and 25 µM).
Ribosomal Proteins Were Negatively
Affected Early Upon Amyloid β Treatment
We identified a significant down-regulation of several
cytoplasmic as well as mitochondrial ribosomal proteins
(21 proteins) in the early stages of the toxicity induced by Aβ
treatment. Down-regulation of ribosomal proteins was identified
at both 5 and 25 µM concentrations and in particular a strong
effect on the protein levels was observed for Rpl29 (0.38–0.51-
fold) and Rps19 (0.51–0.62-fold) proteins. Interestingly, the
down-regulation of ribosomal proteins was alleviated when
the photoreceptor cells were incubated with Aβ (5 µM) for
longer time (24 h) with both Rpl29 and Rps19 demonstrating
an opposite trend. These time dependent effects of Aβ were
also observed in the cells treated with Aβ (25 µM) treated for
24 h. Both Rpl29 and Rps19 along with Rpl36a1 demonstrated a
strikingly opposite effect with 1.75–1.2-fold protein upregulation
(Figure 5). These results suggested that protein synthesis and
elongation pathways were differentially affected by Aβ in the
photoreceptor cells and the effects were dependent on both
concentration of Aβ as well as duration of treatment.
Initial Down-Regulation of Oxidative
Phosphorylation Associated Pathways
In our dataset we identified the subset of proteins associated with
the oxidative phosphorylation and mitochondrial dysfunction,
which were differentially perturbed upon Aβ treatment.
Interestingly, most of the proteins identified in this category
(13 proteins) were negatively affected at both the 5 and 25 µM
concentrations at 6 h time-point which evidently indicated that
this pathway was affected early upon exposure to Aβ. Amongst
these proteins Ndufs4 (0.7-fold) and Atp6v1g1 (0.65-fold)
were prominently down regulated. The downward trend was
blocked when cells were treated with lower concentrations
(5 µM) of Aβ for 24 h. A prominent modulatory effect was
observed in the photoreceptor cells treated with Aβ at higher
concentrations (25 µM) for 24 h with most of the proteins
demonstrating increased levels. The two most down-regulated
proteins Ndufs4 and Atp6v1g1 (5 µM, 6 h) showed an increase
of 1.18 and 1.38-fold, respectively when treated with 25 µM
Aβ for 24 h. Atp6v0c exhibited an increase of 1.51-fold but
it is important to highlight that some of the proteins such as
mt-Co3 and Ppa2 that largely remained unchanged at lower
concentrations of Aβ (5 µM, 6 h) were negatively affected
(0.78–0.9-fold, respectively) at high concentration/longer time
(25 µM, 24 h) treatments. Incidentally, several of the protein
expression changes caused by Aβ treatment paradigms coincided
with the way these pathways are affected in AD (10 proteins;
Ke et al., 2012; Mangieri et al., 2014). APP expression was
not altered in any of the treatment groups suggesting that
although these changes are induced by Aβ but were not
mediated through potential changes in parent APP protein.
Interestingly, two of the affected proteins linked with oxidative
phosphorylation Ndufa7 and Ndufs4 were also associated with
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FIGURE 2 | Heatmaps (hierarchical clustering) of the log-transformed ratios of differentially expressed proteins [differences between all experimental conditions via
analysis of variance (ANOVA)] after Amyloid β (Aβ) treatments; row clustering only. Column colors indicate treatment type and the cluster patterns are detailed on the
side plots.
Sirtuin signaling. Several other proteins of Sirtuin signaling
(total seven proteins) were identified in the study and most
proteins associated with this pathway showed a similar trend
with protein down-regulation at 6 h and up-regulation at 24 h
time points.
Spliceosome Associated Pathways Are
Induced by Aβ Upon Long Term Treatment
Several components of the spliceosome were identified
(10 proteins) as differentially expressed across these four
Aβ treatment groups suggesting that spliceosome and the
mRNA processing were affected by Aβ. A closer look
indicated that several proteins were either downregulated
or unchanged at 6 h time-point at both the concentrations.
However, at 24 h, several proteins demonstrated upregulated
expression and the extent of protein upregulation was more
pronounced when the photoreceptor cells were treated with
higher concentrations of Aβ (25 µM). The most noticeable
indication of protein upregulation with respect to time was
evident for Rbmxl1 (0.78–1.1-fold change for 5 µM and
0.84–1.42-fold change 25 µM). In contrast, Isy1 exhibited an
opposite effect with protein downregulation across both these
concentrations when incubated with Aβ for 24 h. RNA binding
motif protein Rbmx was unchanged at 5 µM (6 h) but was
significantly modulated with increase in incubation time at both
these concentrations.
Reorganization of Cytoskeleton Networks
and Effects on Cellular Viability
Another prominent biochemical module that was differentially
affected with respect to Aβ treatment was actin cytoskeleton
(28 proteins) and keratin filament expression (six proteins).
Network analysis of these proteins reflected that the pathways
associated with mechanical support to cellular shape and internal
organizations were affected. Many proteins in this network node
were typically either unaffected or marginally downregulated in
6 h treatment for both 5 and 25 µM. At longer time point of
24 h treatment group, the proteins were again either unaltered or
demonstrated slightly elevated levels. While, a greater proportion
of proteins were up-regulated in the photoreceptor cells treated
with higher concentrations (25 µM) for longer time (24 h).
Interestingly, tropomodulin 2 showed a reverse trend with
significant upregulation at 5 µM, 6 h (1.45-fold) and then
a subtle downward trend at 24 incubation time. Murc and
Pfn2 were two other proteins that were induced at 5 µM,
6 h but were not altered in other experimental paradigms
compared to control cells. Keratin filament associated proteins
intriguingly demonstrated a reverse trend with consistent protein
upregulation in early stages of the Aβ treatment (6 h) at both
5 and 25 µM concentrations. The upregulation trend indeed
was more prominent at 5 µM concentration. In contrast, the
keratin associated proteins showed no expression changes when
incubated for 24 h with 5 µM Aβ and a slight downregulation
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FIGURE 3 | (A) Volcano plots demonstrating the dual thresholds for differentially regulated proteins. Proteins within the upper and outer quadrants meet both the
fold change and p-value cut-off and are therefore considered as differentially regulated. (B) Venn diagram indicating the overlap between the differentially expressed
proteins identified and quantified in cells after treated for 6 h and 24 h, respectively (1% FDR). (C) Venn diagram indicating the overlap between the differentially
expressed proteins identified and quantified in T1 and T3 (1% FDR). (D) Venn diagram indicating the overlap between the differentially expressed proteins identified
and quantified in T2 and T4 (1% FDR).
across the spectrum of these proteins was evident when the
photoreceptor cells were incubated with the 25 µM peptide
for 24 h. Tau is major cytoskeleton protein that undergoes
increased phosphorylation under AD conditions (Bloom, 2014).
We sought to investigate Tau expression and phosphorylation
changes in the photoreceptor cells in response to Aβ treatment.
Our results indicated enhanced phosphorylation of Tau in
response to Aβ treatment across both the concentrations.
Tau phosphorylation was particularly elevated when the cells
were treated with higher concentrations of Aβ (25 µM) at
both the time-points (Figure 6). No significant Tau protein
expression changes were observed in any of the groups.
Parallel to Tau hyperphosphorylation (Ser202/Thr205), we also
observed increased GSK3β phosphorylation in response to Aβ
treatment. GSK3β dysregulation has strongly been implicated
in AD pathogenesis and promotes cellular senescence (Reddy,
2013). The Ser/Thr kinase is shown to play a role in both
Aβ production and its toxic effects leading to neuronal death
(Hernandez et al., 2013). We observed initial upregulation of
GSK3β phosphorylation at both the concentrations (6 h) which
was found to be subsequently decreased at 24 h (Figure 7). We
sought to investigate whether Aβ treatment led to cell survival
changes in photoreceptor cells at different concentrations of the
peptide (5, 15 and 25 µM) over a period of time (0–24 h).
Our findings suggest that cell viability was inversely related
to the Aβ dose and time of treatment (Figure 8). MTT data
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FIGURE 4 | (A) Top 10 regulated proteins in four treatments. (B) Comparison of the top canonical pathways enriched from ingenuity pathway analysis (IPA) analysis
of differentially regulated proteins (treatment vs. control) in four treatments. The significance of functional enrichment is highlighted with red color. (C) Functional
interaction networks analyzed by the String Cytoscape plugin. One-hundred and one differentially expressed proteins were in pathways related to Alzheimer’s
disease (AD). Network nodes are labeled with gene symbols.
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FIGURE 5 | Heatmap of the regulated proteins in pathways related to AD.
Red and green colors indicate relative increase or decrease in protein
abundance, respectively.
FIGURE 6 | 661 W Cells (1 × 106) were cultured in plates and treated with
5 µM and 25 µM Aβ concentrations and harvested after 6 h and 24 h
respectively. Cells were washed with ice cold 1× PBS, homogenized and
subjected to (A) western blotting and probed with indicated antibodies- pTau
Ser202/Thr205 (1:1,000), Tau (Tau46, 1:1,000) Anti-beta Actin (1:10,000).
Blots were subjected to chemiluminescent substrate detection for HRP linked
secondary antibody and (B) quantified by densitometric analysis (∗∗p < 0.05,
∗p < 0.01).
at least partially reflects the reduced mitochondrial function
that was also identified in mass spectrometry data upon Aβ
treatment in 661 W cells. Together, these results indicate that
toxic effects of Aβ might be linked with impaired cytoskeleton
and underlying aberrations with filamentous architecture and
that these effects correlated with increased Tau phosphorylation,
GSK3β dysregulation and reduced cell viability.
DISCUSSION
Aβ has been shown to induce toxicity effects in the retina
with ageing and in various disease conditions (Gupta et al.,
2014, 2016a,b; Mirzaei et al., 2017a). This study established
that Aβ 1–42 fragment induced significant perturbations in
various biochemical networks in the photoreceptor neurons in
culture conditions. We identified that Aβ 1–42 fragment which
is known to exhibit toxic effects in CNS induced significant
perturbations in the expression of various proteins in the 661 W
photoreceptor cells. The effects of Aβ were highly dependent
on the peptide concentration and the duration of exposure.
Analysis of the proteomics changes indicated that timing of
exposure had a more profound effect in inducing overall
proteome changes in photoreceptor cells rather than the peptide
concentration by itself. The major biochemical pathways that
were affected in response to Aβ treatment were ribosomal protein
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FIGURE 7 | 661 W Cells (1 × 106) were cultured in plates and treated with
5 µM and 25 µM Aβ concentrations and harvested after 6 h and 24 h
respectively. Cells were washed with ice cold 1× PBS, homogenized and
subjected to (A) western blotting and probed with indicated antibodies-
pGSK3β Ser9 (1:1,000), GSK3β (1:1,000), Anti-beta Actin (1:10,000). Blots
were subjected to chemiluminescent substrate detection for HRP linked
secondary antibody and (B) quantified by densitometric analysis
(∗∗∗p < 0.001, ∗∗p < 0.05, ∗p < 0.01).
FIGURE 8 | 5 × 103 cells per well were seeded in 96-well plate in triplicates
for different groups. Cells were treated with 5, 15 and 25 uM of Aβ (1–42) for
three different time durations 6 h, 15 h, and 24 h. At the end of respective
treatments media was discarded and MTT reagent [3-(4,5-Dimethyl
-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide, M5655, Sigma Aldrich]
was added to the wells at a final concentration of 0.5 mg/ml and incubated in
a 37◦C, CO2 incubator for 4 h for reduction of MTT to purple Formazan
crystals. These crystals were dissolved in 200 µl of DMSO and incubated for
15–30 min with gentle shaking. The absorbance of the solution was read at
570 nm and percent viability was calculated.
synthesis, oxidative phosphorylation, cytoskeleton associated
proteins, lysosomal regulation and mRNA processing machinery
of spliceosomes.
Ribosomal dysfunction has been demarcated as one of
the initial processes in AD pathogenesis (Ding et al., 2005).
Several genes associated with protein initiation, translation and
elongation have been shown to be abnormally affected in the
ribosomes (Hernandez-Ortega et al., 2016). Ribosomes are the
site of initiation of protein synthesis and its elongation and we
identified that both mitochondrial and cytoplasmic ribosomal
proteins were affected. Indeed mitochondrial dysfunction has
consistently been reported in AD associated neurodegeneration
(Lunnon et al., 2017) and Aβ has been shown to localize at the
mitochondrial membrane, which may be one of the sites of Aβ
toxicity effects, potentially through its inhibition of pre-protein
maturation (Spuch et al., 2012; Mossmann et al., 2014). Data
analysis signified downregulation of ribosomal proteins in the
early stages of Aβ treatment (6 h) that rebounded to its
initial levels when incubated for longer period of time (24 h)
particularly at the higher concentrations of Aβ (25 µM). These
differential effects of Aβ may be attributed to recovery of the
cells from stress induced by the peptide during initial phases of
incubation and subsequent bouncing back of the biochemical
processes. Increased clearance of Aβ from the cells either due
to its aggregation, internalization in the lysosomes or proteolytic
digestion may also lead to reduced effects of Aβ over a period
of time. Indeed, in this respect, we also observed concomitant
upregulation of lysosomal proteins in the early phases of Aβ
treatment (6 h) at both the concentrations that subsided over a
period of time and demonstrated even a subtle downregulation
of lysosomal proteins (24 h). Autophagy-lysosomal system is
believed to be one of the key mechanisms to eliminate Aβ and its
impaired status in AD is an important focus of drug development
(Tarasoff-Conway et al., 2015). Autophagy of misfolded and
aggregated proteins through lysosomal-endosomal system has
been shown to protect against retinal neuro-inflammation and
degeneration associated with drusen in macular degeneration
(Buschini et al., 2011; Sinha et al., 2016). Aβ assemblies have been
extensively reported in drusen deposits in the retina that might
be involved in chronic complement activation and photoreceptor
degeneration (Johnson et al., 2002; Schuman et al., 2009).
Aβ along with Tau protein together induce a decline in
oxidative phosphorylation in animal models of AD (Rhein
et al., 2009). Altered metabolism of APP has been shown to
associate with mitochondrial dysfunction in primary cortical
neurons in AD and in other disease conditions associated
with anomalous Aβ processing such as in down’s syndrome
(Busciglio et al., 2002; Casley et al., 2002; Mao and Reddy, 2011).
We identified that Aβ treatment induced a downregulation
of several proteins associated with mitochondrial regulation
and oxidative phosphorylation (Figure 5). Interestingly, the
differential regulation of proteins was more evident at 6 h at
either concentration compared to the 24 h suggesting that this
key cellular process is affected early upon exposure to Aβ and
might comprise an initial event of the peptide toxicity. The
protein changes seemingly recovered at the longer time point of
24 h with some of the proteins showing significant upregulation.
Remarkably, a substantial overlap of several of the oxidative
phosphorylation proteins was observed with the proteins that
are affected in AD (Figure 5). APP expression remained largely
unaltered in various experimental conditions suggesting that
observed proteomics variations were not indirectly mediated
through potential effects of Aβ on endogenous APP expression.
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Parallel to the mitochondrial machinery, sirtuin signaling
demonstrated a significant downward trend in the initial phases
of Aβ exposure that either returned back to initial levels or was
upregulated at 24 h (Figure 5). Tau protein accumulation has
been shown to be inversely associated with Sirtuin signaling in
AD (Julien et al., 2009). This pathway is implicated in protecting
the cells against Aβ toxic effects by its inhibitory effects on NFκB
signaling (Chen et al., 2005). SIRT1 was shown to negatively
regulate the mTOR signaling (Ghosh et al., 2010) and this study
revealed an inverse correlation between differential regulation of
Sirtuin and mTOR signaling at higher concentrations of 25 µM
peptide in the photoreceptor cells (Figure 4B). More recently,
SIRT3, a key component of sirtuin signaling has been shown to
impart neuroprotection against light toxicity in the retina and its
suppression led to increased ROS production in 661W cells (Ban
et al., 2017).
Proteomics studies have previously implicated RNA splicing
defects in AD (Ke et al., 2012). Nuzzo et al. (2017) recently
identified spliceosome impairment as a prominent pathway
that was affected in LAN5 neuroblastoma cells upon Aβ
treatment (Nuzzo et al., 2017). Mutations in splicing factors
Rp9, DHX38 and several snRNP proteins such as PRPF3 have
independently been shown to lead to photoreceptor degeneration
and form aggregates in 661 W photoreceptor cells (Comitato
et al., 2007; Lv et al., 2017; Ruzickova and Stanek, 2017).
Aβ treatment of 661 W photoreceptor cells in this study
revealed subtle downregulation or no change in the initial
stages of peptide treatment (6 h), however several proteins
were upregulated 24 h following treatment with higher Aβ
concentrations (25 µM). These findings supported the premise
that alterations in RNA splicing may be induced at a relatively
prolonged exposure to Aβ. It is important to highlight that
there was also a recovery of ribosomal protein levels at this
time-point (Figure 5), which could potentially underlie an
increased synthesis of spliceosome associated proteins in the
ribonucleoprotein particle (RNP) assemblies.
Finally, anothermajor biochemical module that was identified
to be differentially regulated was the actin cytoskeleton and
keratin filament associated protein network. Cytoskeleton
associated proteins demonstrated a slight upregulation when
exposed to peptide concentration of 25 µM for 24 h
(Figure 5). Under normal conditions there is a constant turnover
between the globular and filamentous cytoskeleton proteins
for the proper cell functioning, however Aβ might affect
the assembly/disassembly of cytoskeleton proteins and impair
cellular adaptability (Cardenas et al., 2012). Supporting our
observations, Aβ treatment has previously been shown to induce
dysregulation of actin cytoskeleton proteins in the neurons by
12–24 h following treatment (Deshpande et al., 2006; Bamburg
and Bloom, 2009). In the retina, sub-retinally injected Aβ
1–42 was shown to induce dis-organization of actin cytoskeleton
in the RPE cells leading to subsequent photoreceptor loss
(Bruban et al., 2009). An interesting observation was the
remarkable enrichment of the keratin filament associated
proteins by Aβ at 6 h time point that basically bounced back
to normal levels at 24 h at lower concentrations of Aβ (5 µM).
This might suggest that keratin proteins are potentially impacted
early in response to Aβ exposure. Keratin 8 has been shown to
protect the RPE cells against oxidative stress induced injury and
keratin 9 was even suggested to be one of the biomarkers of AD
(Richens et al., 2016), although it is plausible that the changes
that we identified in this study are 661 W cell specific owing to
their retinal origin. Tau is another major cytoskeleton associated
protein that undergoes hyperphosphorylation in AD and forms
intracellular tangles. Increased Tau phosphorylation observed
in this study in response to high Aβ concentrations for longer
period corresponded with GSK3β activation (Figures 7, 8).
Conversely, at low concentrations of Aβ (5 µM, 6 h), GSK3β
was inactivated and accordingly no Tau phosphorylation changes
were observed. The two proteins have been suggested to play
key converging roles in AD pathogenesis (Hernandez et al.,
2013) with GSK3β inducing Tau phosphorylation as a substrate
in cells (Avila et al., 2012). Increased Tau phosphorylation
(25µM, 24 h) interestingly, also corresponded with upregulation
of expression of several other cytoskeleton associated proteins
(Figure 5) observed at higher concentrations of Aβ (25 µM,
24 h). GSK3β inhibition in response to 6 h Aβ treatment (5 and
25 µM) observed here, may be an early event when the cells
are trying to counter the neurotoxic effects of the peptide by
activating neuroprotective pathways. Aβ-induced neurotoxicity
has previously been shown to be reduced upon GSK3β inhibition
(Koh et al., 2008). Following 24 h of incubation, GSK3β
was observed to be in an activated state across both Aβ
concentrations. It is possible that these time dependent effects
of Aβ on GSK3β activity is a 661 W photoreceptor cell specific
response, and future in vivo studies will unravel the molecular
basis of these actions in comparison with other neuronal cells.
Changes in GSK3β activation state in response to Aβ treatment
match the trends identified in our other results where we
observed that proteome profile of 661 W photoreceptor cells was
similarly affected when treated for 6 h at either 5 or 25 µM Aβ
concentrations. A distinct pattern of protein changes was also
evident within the cells that were subjected to 24 h treatment
(5 and 25 µM).
We selected a low concentration of 5 µM and a moderately
higher concentration of 25 µM to study the effects of the Aβ
peptide on the photoreceptor cells. At 25 µM, we observed
significant enrichment of the autophagy canonical pathway in
the cells (Figure 4B) suggesting that treating the cells with a
much higher concentration could have induced rampant cell
death and confound the protein expression changes within the
cells. This study revealed initial proteomics changes without
the confounding effects of the widespread apoptosis and cell-
death. Cell survival assays at different concentrations of Aβ and
incubation timings revealed an inverse relationship with cellular
viability. These studies further demonstrated that molecular
degenerative changes delineated in this study, in response to Aβ
treatment play a key role in photoreceptor cell survival under
culture conditions. Further, other fragments of Aβ, such as Aβ
1–40 and Aβ 1–16 are known and exhibit distinct biological
functions. Pharmacological treatments with these fragments
may differentially affect various biochemical pathways in these
cells. It is however pertinent to mention that Aβ 1–42 is
considered highly toxic compared to other smaller fragments, is
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generally present at a much higher concentration compared to
Aβ 1–40 and is also more prone to aggregate formation (Suh and
Checler, 2002; De Strooper, 2010; Gupta et al., 2014).
While autophagy pathways were observed to be upregulated,
we could not identify caspase activation in response to Aβ
treatment in 661 W photoreceptor cells. Caspase activation has
previously been reported in other cell lines upon Aβ treatment
and in AD brains (Dickson, 2004; Sharoar et al., 2014). These
differences could be attributed to possibly lower expression of
these proteins in 661 W cells or different mechanisms of Aβ
toxicity in retinal cells. The extensive alterations in proteome
profile caused by Aβ in the photoreceptor cells is important,
although the exact physiological functions of APP or disease
specific roles of Aβ in the outer retina are not known. This can
be studied by performing intravitreal injections of Aβ 1–42 in
the animals and determining molecular changes in the retina.
It is possible that in the retina many of the implication of the
peptide related to its toxicity effects are sub-clinical and not easily
identifiable with current imaging tools. We provide these data as
a resource for future investigations in animal and human studies,
which are needed to conclusively establish the biochemical effects
of Aβ in the retina, which can then be used for therapeutic
targeting. Follow up investigations on the mechanisms of action
of the Aβ peptide will determine sequelae of biochemical events
that are triggered in response to the peptide in the photoreceptors
and other retinal neurons such as in retinal ganglion cells that are
particularly affected in glaucoma and AD pathology (Gupta et al.,
2014, 2016a,b).
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